MedStar Health: Neurology at McLean
McLean, Virginia, 22101, United States
Location status: Recruiting
NCT Number: NCT07301008
Single-center, open label, prospective study conducted at Medstar Georgetown Headache Center. Men and woman ≥ 18 years old that are diagnosed with migraine with or without aura for at least 1 year, who report a reliable migraine trigger. Acceptable triggers for the study will include exercise, alcohol (less than one drink per day for woman and less than two drinks per day for men), air travel that lasts no more than 12 hours, sexual activity, fasting that lasts no more than 24 hours, stress or stress let-down headache.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Phase 4
McLean, Virginia, 22101, United States
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The interventional product is rimegepant ODT 75 mg. Rimegepant 75mg ODT will be given 2 hours prior to a trigger exposure for exercise, alcohol (less than one drink per day for woman and less than two drinks per day for men), air travel that lasts no more than 12 hours, sexual activity, fasting that lasts no more than 24 hours rimegepant will be dosed 2 hours prior to trigger exposure. For weekend or let down headache and changes in sleep pattern, rimegepant will be dosed the night before. The maximum dose in a 24-hour period is 75mg.
Time frame: 24 hour post dose
Percentage of preemptive treatments with rimegepant in which migraine with a moderate to severe headache intensity occurs within 24 hours
Time frame: 24 hour, 48 hour post dose
Percentage of preemptive treatments with rimegepant in which migraine occurs within 24 hours
Time frame: At the end of the study completion( 2 month after enrollment)
Patient satisfaction with preemptive rimegepant treatment will be assessed in the case report form using a Likert scale
Time frame: At the end of study completion( 2 months after enrollement)
The effect of preemptive treatment with rimegepant on Patient Global Impression of Change (PGIC) using a graded scale of 1-7.
Contact information is provided by the study sponsor or research team.
Medstar Health Research Institute
Other
Acronym: RIM
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07645924
Brain Diseases, Central Nervous System Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT05125302
Brain Diseases, Central Nervous System Diseases
Huntsville, Alabama, United States
View Trial DetailsNCT06972056
Brain Diseases, Central Nervous System Diseases
Flagstaff, Arizona, United States
View Trial DetailsNCT07720765
Alzheimer Disease, Autoimmune Diseases
Milan, Milano, Italy
View Trial Details